TY - JOUR
T1 - Bratislava Statement: Consensus recommendations for improving pancreatic cancer care
AU - Prades, Joan
AU - Arnold, Dirk
AU - Brunner, Thomas
AU - Cardone, Antonella
AU - Carrato, Alfredo
AU - Coll-Ortega, Cristina
AU - De Luze, Samuel
AU - Garel, Pascal
AU - Goossens, Maria E.
AU - Grilli, Roberto
AU - Harris, Meggan
AU - Louagie, Marleen
AU - Malats, Núria
AU - Minicozzi, Pamela
AU - Partelli, Stefano
AU - Pastorekova, Silvia
AU - Petrulionis, Marius
AU - Price, Richard
AU - Sclafani, Francesco
AU - Smolkova, Bozena
AU - Borras, Josep M.
N1 - Funding Information:
Funding This report arises from the Innovative Partnership for Action Against Cancer Joint Action, which has received funding from the European Union through the Consumers, Health, Agriculture and Food Executive Agency of the European Commission, in the framework of the Health Programme 2014–2020.
Publisher Copyright:
©
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/11/13
Y1 - 2020/11/13
N2 - Pancreatic cancer is one of the most lethal tumours, and it is the fourth cause of cancer death in Europe. Despite its important public health impact, no effective treatments exist, nor are there high-visibility research efforts to improve care. This alarming situation is emblematic of a larger group of cancer diseases, known as neglected cancers. To address the impact of these diseases, the European Commission-supported Innovative Partnership for Action Against Cancer launched a multi-stakeholder initiative to determine key steps that healthcare systems can rapidly implement to improve their response. A working group comprising 20 representatives from European medical societies, patient associations, cancer plan organisations and other relevant European healthcare stakeholders was organised. A consensus process based on the results of different studies, discussion of research outcomes, and development and endorsement of draft statements resulted in 22 consensus recommendations (the Bratislava Statement). The statement argues that substantial improvements can be achieved in patient outcomes by centralising pancreatic cancer care around state-of-the-art reference centres, staffed by expert multidisciplinary teams capable of providing high-quality care. This organisational model requires a specific care framework encompassing primary, palliative and survivorship care, and a policy environment prioritising the use of quality criteria and performance assessments as well as research investments dedicated to prevention, risk prediction, early detection and diagnosis. In order to address the challenges posed by neglected cancers in general and pancreatic cancer in particular, a specific control strategy tailored to this reality is required.
AB - Pancreatic cancer is one of the most lethal tumours, and it is the fourth cause of cancer death in Europe. Despite its important public health impact, no effective treatments exist, nor are there high-visibility research efforts to improve care. This alarming situation is emblematic of a larger group of cancer diseases, known as neglected cancers. To address the impact of these diseases, the European Commission-supported Innovative Partnership for Action Against Cancer launched a multi-stakeholder initiative to determine key steps that healthcare systems can rapidly implement to improve their response. A working group comprising 20 representatives from European medical societies, patient associations, cancer plan organisations and other relevant European healthcare stakeholders was organised. A consensus process based on the results of different studies, discussion of research outcomes, and development and endorsement of draft statements resulted in 22 consensus recommendations (the Bratislava Statement). The statement argues that substantial improvements can be achieved in patient outcomes by centralising pancreatic cancer care around state-of-the-art reference centres, staffed by expert multidisciplinary teams capable of providing high-quality care. This organisational model requires a specific care framework encompassing primary, palliative and survivorship care, and a policy environment prioritising the use of quality criteria and performance assessments as well as research investments dedicated to prevention, risk prediction, early detection and diagnosis. In order to address the challenges posed by neglected cancers in general and pancreatic cancer in particular, a specific control strategy tailored to this reality is required.
KW - delivery of health care
KW - health policy
KW - pancreatic neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85096154220&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096154220&partnerID=8YFLogxK
U2 - 10.1136/esmoopen-2020-001051
DO - 10.1136/esmoopen-2020-001051
M3 - Review article
C2 - 33188052
AN - SCOPUS:85096154220
VL - 5
JO - ESMO Open
JF - ESMO Open
SN - 2059-7029
IS - 6
M1 - e001051
ER -